Why Indian Drug Makers Challenge Global Patents
Explore the high-stakes legal battles between Indian generic manufacturers and global pharma giants. Understand the impact on drug prices, accessibility, and the evolving IP landscape in India.
Category : Search result: Novo Nordisk Eli Lilly
Natco Files to Revoke Novo Nordisk's Wegovy Patent in India
Hyderabad's Natco Pharma petitions Delhi High Court to revoke Novo Nordisk's semaglutide patent. The legal battle shapes India's future weight-loss drug market as 2026 patent expiry nears. Read more.
Novo Nordisk launches Wegovy weight-loss pill in US
Novo Nordisk launches oral Wegovy weight-loss drug in the US, priced at $299. The pill, approved in Dec 2025, aims to regain market share from rival Eli Lilly. UK approval expected end-2026.
Novo Nordisk: Wegovy Price Cut to Boost India Obesity Therapy 5-7x
Novo Nordisk expects India's obesity drug market to grow rapidly after a 37% Wegovy price cut, mirroring insulin uptake. Generic competition looms with a Rs 5000-crore opportunity.
Ant-Man's Evangeline Lilly shares health update after brain injury
Ant-Man star Evangeline Lilly discloses traumatic brain injury results, revealing decreased brain function. Read her emotional update and road to recovery.
Evangeline Lilly Shares Shocking Brain Injury Update
Marvel star Evangeline Lilly reveals traumatic brain injury diagnosis after a 2025 fall. Get the full health update and her recovery journey here.
Evangeline Lilly reveals brain damage diagnosis
Marvel star Evangeline Lilly shares a traumatic brain injury diagnosis after a 2025 accident in Hawaii. She details her recovery journey and life reassessment. Read her full story.
Weight-Loss Pill Race in 2026: Lilly Leads Novo Nordisk
Novo Nordisk and Eli Lilly to launch oral GLP-1 drugs in 2026. Despite Novo's head start, analysts predict Lilly's market leadership in obesity and diabetes treatments will persist for years. Explore the details.
FDA Approves Daily Wegovy Pill for Weight Loss
US FDA approves Novo Nordisk's daily Wegovy pill, an oral alternative to injections. Priced from $149, it offers 14% average weight loss. Details on cost, side effects, and how it compares to rivals.
Novo Nordisk stock jumps 7% on FDA approval for Wegovy pill
Shares of Novo Nordisk surged over 7% after its weight loss drug Wegovy pill received US FDA approval on December 22, 2025. Read the full market impact analysis.
First Weight-Loss Pill Approved in US, Priced $149/Month
US FDA approves Novo Nordisk's Wegovy Pill, first oral GLP-1 drug for weight loss. Priced at $149/month, it promises wider access and challenges injectable dominance. Read more.
Emcure Enters Obesity Market with Novo Nordisk's Semaglutide
Emcure Pharmaceuticals launches Poviztra, a weekly semaglutide injection for weight loss, in partnership with Novo Nordisk. Priced from ₹2,200 per week, it targets India's massive obesity market.
Lucas Bravo Reveals His Biggest Pet Peeve in Conversations
Emily in Paris star Lucas Bravo opens up about hating small talk, his journey to landing Gabriel's role, and his love for deep conversations about life and growth. Read more!
Sydney Holds First Funeral for Bondi Beach Shooting Victim
Australia mourns Rabbi Eli Schlanger as first funeral held for Bondi Beach shooting victims. PM Albanese vows action on antisemitism. Latest updates on the Sydney tragedy.
Sydney Shooting: Holocaust Survivor, Rabbi Among 15 Dead
A Holocaust survivor shielding his wife and a community rabbi are among the 15 victims of the Sydney mass shooting. Read about the heroes and the global tributes.
Court Rejects Ozempic Patent Extension, Boosts Generic Drug Access
Delhi High Court rejects Novo Nordisk's patent plea on semaglutide (Ozempic/Wegovy), preventing 'evergreening'. A win for affordable generics in India, but raises concerns over non-clinical misuse of weight-loss drugs. Read more.
Delhi HC sides with Dr Reddy's in semaglutide patent case
Delhi High Court rejects Novo Nordisk's plea for interim injunction against Dr Reddy's Labs over semaglutide. Court cites 'evergreening', allows DRL to export. Key ruling for diabetes drug market.
India's Drug Patent Wars: Need for Special Courts?
A recent Delhi High Court order in the Novo Nordisk vs Dr Reddy's case highlights the complexities of Indian patent litigation. We examine the system's challenges and the push for specialized IP courts.
Dr Reddy's Wins Delhi HC Nod to Export Semaglutide
Delhi High Court permits Dr Reddy's to export generic semaglutide, a major win for Indian drugmakers eyeing the booming anti-obesity market. Read the full analysis.
Eli Lilly Slashes Zepbound Price in Obesity Drug Battle
Eli Lilly reduces Zepbound's starting price to $299 monthly, intensifying its price war with Novo Nordisk's Ozempic and Wegovy. New discounts aim to expand access to blockbuster weight-loss drugs.
Oral GLP-1 Pill Orforglipron Shows Weight Loss Success
Eli Lilly's oral GLP-1 drug Orforglipron offers needle-free weight management with significant results in Phase 3 trials. Discover how this tablet alternative works.
Lilly Singh: Women Aren't Funny? That's Dumb!
Exclusive interview with Lilly Singh on sisterhood, digital creators' respect, Hollywood diversity struggles, and why women comedians face unfair criticism. Read her powerful insights!
Oral Weight-Loss Pill Orforglipron: Ozempic 2.0
Eli Lilly's daily pill orforglipron shows 12% weight loss in trials, potentially revolutionizing obesity treatment. Could this be the end of injections?
Oral Ozempic 2.0: Game-Changer Weight Loss Pills
Novo Nordisk and Eli Lilly develop daily oral weight loss pills with 10-16% average weight loss in trials. Pending FDA approval, these could replace injections.
Missouri QB Beau Pribula set for shock return vs Oklahoma
Missouri Tigers QB Beau Pribula is set to start against Oklahoma Sooners just four weeks after a dislocated ankle injury. Coach Drinkwitz confirms his availability for the pivotal road game.
Eli Lilly First Pharma to Reach $1 Trillion Market Cap
Eli Lilly makes pharmaceutical history as first company to achieve $1 trillion market capitalization after shares rose 1.7% on November 21, 2025. Learn what this means for investors.
Alzheimer's Drug Donanemab Approved in India
Eli Lilly's Alzheimer's drug donanemab gets Indian regulatory approval. The treatment slows cognitive decline by 35.1% and could be available next year. Learn about its benefits and pricing.
Alzheimer's Drug Donanemab Approved for India
Eli Lilly's Alzheimer's drug donanemab gets Indian regulator nod. The treatment slows cognitive decline by 35.1% and is expected to launch in India next year. Details on pricing and safety.
Novo Nordisk Cuts Wegovy Price, Eyes Oral Pill Launch
Novo Nordisk reduces Wegovy's price to $349 and prepares an aggressive launch for its oral weight-loss pill to combat competition from Eli Lilly and expand patient access.
Novo Nordisk brings back former CEO as chairman
Lars Rebien Sorensen returns as Novo Nordisk chairman after board shakeup. The move follows Pfizer's $10B Metsera acquisition, intensifying obesity drug competition.
Page 1 of 2